Search

everythinglearnresearchcommunity

for

Search:↓

A clinical trial for hair loss treatments involving Minoxidil, Finasteride, and RU58841, and when the results of the trial will be available.

Dutasteride may be better for the brain than Finasteride, potentially increasing dopamine levels and causing fewer side effects. For those switching from Finasteride to Dutasteride to prevent hair loss, it's recommended to continue Finasteride for 3-4 months while starting Dutasteride to avoid shedding due to Dutasteride's long half-life.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

The hair loss treatment Pyrilutamide and whether it has had any results for users. Martinsahara is planning to buy some soon.

The user is frustrated about not hearing any updates on the HMI-115 trial for hair loss. They are questioning if there will be any updates in the future.

The conversation is about the effectiveness of Breezula for hair loss, with skepticism expressed due to lack of scientific proof and mixed results from those using Breezula and RU58841. Some are waiting for clinical trial results before trying treatments like Breezula and SM04554.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also mentions an update on Dr. Bloxham's Verteporfin treatment.

Minoxidil is used for hair loss and sometimes for high blood pressure, but it's outdated for the latter. For high blood pressure, it's combined with a beta blocker and diuretic to manage side effects.

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

The user is using Minoxidil, RU58841, CB-03-01, WAY-316606, Ketoconazole, MK-677, and derma stamping to treat hair loss and has noticed new hair growth, especially around the temples and hairline. They apply different treatments at various times of the day and have seen improvements in skin condition and body hair texture.

Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.

The user tried minoxidil 5% for 3 years with little improvement, then switched to a 15% minoxidil with 0.1% finasteride solution once daily and started using pyrilutamide, resulting in significant hair regrowth over time. They are considering a hair transplant but are continuing with topical treatments to maximize hair growth first.

Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.

Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.

A 7-month progress report of using finasteride and minoxidil, as well as keto dieting and derma stamping; the discussion also touched on RU58841 and its potential side effects.

Vat-R-U-Talkin-About: I'm not sure that wearing a hat would have an effect on either Minoxidil or Finasteride. It may be worth experimenting with not wearing one for a few weeks to see if it makes any difference. This conversation is about a user's progress pictures four months into taking minoxidil, finasteride, and nizoral twice weekly to treat hair loss; others shared their experiences and offered advice on how to improve the treatment.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

Hair cloning and injection of dermal papilla cells are discussed, with skepticism about their availability by 2023. Users mention Minoxidil, finasteride, and hair transplants as current treatments.

L'Oreal is working on hair cloning, with multiple companies using similar techniques, making hair cloning likely by 2030. The conversation expresses optimism about the progress and potential affordability of hair cloning solutions.

The conversation is about someone planning to use cb-03-01 for hair loss because they experience side effects with other treatments like finasteride, minoxidil, and RU58841. They have not found progress pictures online and are considering sharing their own experience with cb-03-01, which is expensive.

Shiseido's hair loss treatment reported only 5% regrowth, disappointing many. Users discussed other treatments like Minoxidil, finasteride, RU58841, and CB-03-01 as potential alternatives.

OP seeks advice on alternative hair loss treatments like Redensyl, Capixyl, and Procapil, instead of lifelong Minoxidil and Finasteride. Users suggest hair transplants and discuss the potential future availability of better treatments.

GT20029, a new hair loss treatment, shows promising results but only a slight improvement over placebo. People are cautiously optimistic, discussing its potential and combining it with existing treatments like Minoxidil and Finasteride.

Some users of RU-58841 report cardiovascular symptoms like heart palpitations and chest tightness, which may be linked to its metabolites causing lung disease. The safety of RU-58841 is uncertain due to lack of long-term data and concerns about product purity, especially from gray market sources.

The conversation is about individuals sharing their positive experiences with hair loss treatments, specifically using oral minoxidil and finasteride, which have improved their hair density and helped them worry less about balding. Some users have been on these treatments for various durations and have noticed maintenance and regrowth of hair.

Researching the effects of scalp trauma on hair growth, with some users suggesting experimenting with a soldering iron or derma pen, and others bringing up studies that suggest this may be an effective treatment.

A hair tattoo substitute for a hair transplant, which many people felt was not a good idea. Several treatments were suggested as alternatives, such as Scalp Micro Pigmentation (SMP) and wigs.

Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.

Hair loss in a 3-year-old, with various treatments discussed such as minoxidil, finasteride, dutasteride, RU58841 and biotin supplementation. Some people suggested shaving the head and growing a beard or getting a partial hairpiece instead of attempting to treat it.

A 16-year-old researching and trying Pyrilutamide for hair loss treatment, reporting back on side effects experienced after one week of use; the reported side effects included testicle pain, headache, and increased shedding. Libido and sexual performance seemed unaffected.